NCT01100684已完成3 期
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Tioga Pharmaceuticals134 个研究点 分布在 1 个国家目标入组 611 人开始时间: 2010年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 611
- 试验地点
- 134
- 主要终点
- 12 Week Abdominal Pain and Stool (APS) Frequency Responder
研究概览
简要总结
The purpose of this study is to determine whether asimadoline is safe and effective at treating D-IBS.
详细描述
The primary objective of the study is to compare the efficacy of the two treatments with respect to improvement in IBS-related abdominal pain severity and reduction in stool frequency. During the 12-week treatment period, daily IBS-related abdominal pain severity score and daily frequency of bowel movements will be averaged over each week to determine average values for each endpoint. For each subject, weekly response to treatment will be based on the following parameters:
- Decrease from baseline of at least 30% in the average IBS-related daily abdominal pain severity score
- Decrease from baseline of at least 25% in the average number of daily bowel movements A subject must meet both criteria to be considered a weekly responder. The primary efficacy endpoint is based on an "overall study responder," defined as a subject having 6 or more weeks of weekly response to treatment out of the 12 weeks in the treatment period. Overall study responder will be stratified by timing of bowel preparation and endoscopy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signs and dates a written informed consent form.
- •Male and female subjects aged 18-79 who are fluent in English
- •All subjects must use protocol specified contraceptive measures
- •The subject is or has been diagnosed with IBS with symptom onset at least 6 months prior to diagnosis. IBS is defined as the subject having recurrent abdominal pain or discomfort at least 3 days per month in the past 3 months associated with at least two of the following symptoms:
- •Improvement with defecation Onset associated with a change in frequency of stool Onset associated with a change in form (appearance) of stool
- •The subject has been diagnosed with diarrhea-predominant IBS
- •Within 2 years of the randomization visit, the subject has normal results from a flexible sigmoidoscopy, a colonoscopy, or a barium enema plus flexible sigmoidoscopy, according to the subject's age by a specified algorithm.
排除标准
- •The subject exhibits evidence of a biochemical or structural abnormality of the digestive tract.
- •Subject has a concurrent illness or disability (excluding IBS) that may affect the interpretation of clinical efficacy and/or safety data or otherwise contraindicates participation in this clinical study (e.g., an unstable cardiovascular, renal, hepatic, pulmonary, endocrine, metabolic, GI, hematological, or neurological condition).
- •The subject has a family history of prolonged QT syndrome.
- •The subject has been diagnosed with a major psychiatric disorder.
- •The subject has a history of alcohol or substance abuse within the past 2 years.
- •The subject has a history or current evidence of laxative abuse
- •The subject has a positive stool sample for ova or parasite.
- •The subject has used an investigational drug or participated in an investigational study within 30 days of screening.
- •The subject refuses to discontinue one (or more) prohibited medications at least 7 days prior to the screening visit.
- •The subject refuses to maintain a stable dose of one (or more) allowable concurrent medications for at least 30 days prior to the screening visit.
- •The subject is a pregnant woman or a woman who is breast feeding.
- •The subject is unable or unwilling to follow directions or use the electronic diary system.
研究组 & 干预措施
Treatment
Experimental
0.5 mg asimadoline bid
干预措施: Asimadoline (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
12 Week Abdominal Pain and Stool (APS) Frequency Responder
时间窗: Weekly responder based on patient assessments made daily in each week of the 12-week Treatment Period to determine 12 week APS responder
A study responder is a subject who has both a decrease from baseline of IBS-related abdominal pain and a decrease from baseline of daily bowel movements
次要结局
- Compare the two treatment groups with respect to IBS-related abdominal pain(Up to 12 weeks)
- Incidence of adverse events as a measure of tolerability(Up to 16 weeks)
- Abnormalities of laboratory tests as a measure of tolerability(Up to 16 weeks)
- Compare the two treatment groups with respect to stool consistency scores(Up to 12 weeks)
- Compare the two treatment groups with respect to stool frequency(Up to 12 weeks)
- Compare the two treatment groups with respect to stool urgency(Up to 12 weeks)
- Compare the two treatment groups with respect to IBS symptoms(up to 12 weeks)
研究者
研究点 (134)
Loading locations...
相似试验
终止
2 期
Asimadoline for the Treatment of Post-Operative IleusPost-Operative IleusNCT00443040Tioga Pharmaceuticals35
已完成
2 期
Asimadoline for the Treatment of Subjects With Irritable Bowel SyndromeIrritable Bowel SyndromeNCT00454688Tioga Pharmaceuticals596
已完成
2 期
MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)Alzheimer's DiseaseNCT00420420Merck Sharp & Dohme LLC144
已完成
3 期
Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With MethotrexateRheumatoid ArthritisNCT00235859Abbott128
终止
2 期
An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With CapecitabineMetastatic Breast CancerNCT00165880Eisai Limited62